Business Wire

Czech Technical-UPenn-NYU Team Wins Grand Challenge in US$5-Million MBZIRC2020 Organized by Khalifa University

Share

H.E. Dr. Mugheer Khamis Al Khaili, Member of the Executive Council, and Chairman of Department of Community Development today honored the Grand Challenge team winners Czech Technical University-University of Pennsylvania-NYU and winners of the three Challenge categories at the three-day US$5-million Mohamed Bin Zayed International Robotics Challenge (MBZIRC) 2020 that concluded in Abu Dhabi, organizers Khalifa University of Science and Technology announced today.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200226005539/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Czech Technical-UPenn-NYU Team Wins Grand Challenge in US$5-Million MBZIRC2020 organized by Khalifa University (Photo: AETOSWire)

The winning teams in all three categories – Challenge 1, 2, and 3 – also received awards from H.E. Dr. Mugheer Khamis Al Khaili at the ceremony.

His Excellency Hussein Bin Ibrahim Al Hammadi, Steering Committee General Chair, MBZIRC 2020, Dr. Arif Sultan Al Hammadi, Steering Committee General Co-Chair, and His Excellency Dr. Mohammed Al Mualla, Steering Committee Member, were present.

Others who attended the ceremony included UAE government officials, Challenge partners, stakeholders from the academia, research, and industry, as well as all the MBZIRC 2020 team members.

The Czech Technical University-University of Pennsylvania-NYU team won the first position in the Grand Challenge. The University of Bonn team came second, while the combined team of Universidad Politecnica Madrid-Universidad Pablo Olvide Poznan University of Technology- Centre National de la Recherche Scientifique won the third place.

The Beijing Institute of Technology topped Challenge 1 category with the Czech Technical University-University of Pennsylvania-NYU team and the University of Tokyo in the second and third places, respectively, while the Czech Technical University-University of Pennsylvania-NYU team won the Challenge 2 category with Nimbro (University of Bonn) and Technical University of Denmark in the second and third places. Challenge 3 was won by University of Seville-Tecnico Lisboa-CATEC team, while the Technical University of Denmark and the University of New South Wales-Sydney tied for the second place.

The 32 finalists, representing 17 countries, were shortlisted out of 134 teams from across the globe that applied to compete in MBZIRC 2020.

Dr. Arif Sultan Al Hammadi said: “The second edition of MBZIRC has emphatically placed MBZIRC as one of the most prestigious competitions in robotics and artificial intelligence globally, while positioning Khalifa University as the leading higher education institution driving innovation in all areas of science, engineering, and newly-emerging technologies.”

Dr. Al Hammadi added: “Congratulations to all the winners of MBZIRC 2020, especially the Grand Challenge winner and winners of all three Challenge categories. However, all the participating teams deserve credit for their commitment, determination and perseverance during the competition, consistently raising the bar of excellence as displayed by various autonomous drones. Through this Challenge, we have witnessed how technology continues to evolve and we firmly believe the advancements demonstrated by these UAVs and UGVs will very soon become part of our everyday lives.”

For more information, please visit: http://www.ku.ac.ae/

*Source: AETOSWire

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

APCO Worldwide
Abdullah Al Sayed, Account Director, +971504887044
aalsayed@apcoworldwide.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye